Abstract
SHIP (SH2 domain containing inositol phosphatases) was identified as a 145kDa multi-domain cytosolic protein expressed specifically in hematopoietic cells that negatively regulates cell growth, survival and proliferation. Aberrant SHIP function is associated with many disease pathologies. There are two aspects to SHIP function: the catalytic function mediated by the central catalytic domain and the non-catalytic function mediated by the protein-protein interaction domains of SHIP. Much is known about the catalytic function of SHIP and its role in regulation of growth factor and immune receptor signaling. However, not much is known about the mechanistic details of the non-catalytic functions of SHIP and this is an active area of research. In this review, we discuss the role of SHIP in different cell types of immune system, its role in various diseases and its potential as a therapeutic target.
Keywords: SH2 domain, SH3 domain, SHIP, catalytic and non-catalytic function of SHIP, PI3K, SHIP-deficient, innate and adaptive immunity
Current Enzyme Inhibition
Title: Targeting the SH2 Domain-Containing Inositol Phosphatase (SHIP) for Therapy
Volume: 5 Issue: 3
Author(s): Payal Mehta, Jonathan P. Butchar and Susheela Tridandapani
Affiliation:
Keywords: SH2 domain, SH3 domain, SHIP, catalytic and non-catalytic function of SHIP, PI3K, SHIP-deficient, innate and adaptive immunity
Abstract: SHIP (SH2 domain containing inositol phosphatases) was identified as a 145kDa multi-domain cytosolic protein expressed specifically in hematopoietic cells that negatively regulates cell growth, survival and proliferation. Aberrant SHIP function is associated with many disease pathologies. There are two aspects to SHIP function: the catalytic function mediated by the central catalytic domain and the non-catalytic function mediated by the protein-protein interaction domains of SHIP. Much is known about the catalytic function of SHIP and its role in regulation of growth factor and immune receptor signaling. However, not much is known about the mechanistic details of the non-catalytic functions of SHIP and this is an active area of research. In this review, we discuss the role of SHIP in different cell types of immune system, its role in various diseases and its potential as a therapeutic target.
Export Options
About this article
Cite this article as:
Mehta Payal, Butchar P. Jonathan and Tridandapani Susheela, Targeting the SH2 Domain-Containing Inositol Phosphatase (SHIP) for Therapy, Current Enzyme Inhibition 2009; 5 (3) . https://dx.doi.org/10.2174/157340809789071182
DOI https://dx.doi.org/10.2174/157340809789071182 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry Editorial (Thematic Issue: Targeted Anti-Cancer Drug Delivery)
Current Cancer Drug Targets Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Angiogenesis in Lymphoma: A Short Review
Current Molecular Medicine Efficient Purification of rhG-CSF and its PEGylated Forms and Evaluation for In Vitro Activities
Protein & Peptide Letters Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets Neuroprotection by vitamin C against ethanol -induced neuroinflammation associated neurodegeneration in developing rat brain
CNS & Neurological Disorders - Drug Targets Therapeutic Antibodies
Current Molecular Medicine Current Status and Future of Target-Based Therapeutics
Current Cancer Drug Targets The Role of B Cells in Multiple Sclerosis: Implications for B-Cell-Targeted Therapy
Current Medicinal Chemistry Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer
Mini-Reviews in Medicinal Chemistry Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity
Current Pharmaceutical Design Antifolates - Past, Present and Future
Current Medicinal Chemistry - Anti-Cancer Agents Safer Vectors for Gene Therapy of Primary Immunodeficiencies
Current Gene Therapy Therapeutic Window, a Critical Developmental Stage for Stem Cell Therapies
Current Stem Cell Research & Therapy Pharmacology and Clinical Effect of Platonin, a Cyanine Photosensitizing Dye: Potential Molecular Targets
Current Pharmaceutical Biotechnology